NDC Compounded Drug 26436-5382-1 Benzocaine; Tetracaine; Lidocaine
Gel Topical
Compounded Drug Product Information
NDC Crossover Products Matching Benzocaine; Tetracaine; Lidocaine
NDC crossover of Blt Topical Gel with NDC 26436-5382 a human compounded drug with other similar products matching the same substance name (Benzocaine; Tetracaine; Lidocaine) and the same administration route (topical) or dosage form (gel).
NDC | Proprietary Name | Non-Proprietary Name | Package Desc | Dosage Form | Route Name | Company Name |
---|---|---|---|---|---|---|
26436-5057-1 | Blt Topical Gel | Blt 20/8/4 | 500 g in 1 JAR | Gel | Topical | Hybrid Pharma |
26436-5433-1 | Blt Dmso Gel | Blt 20/8/4 Dmso | 60 g in 1 JAR | Gel | Topical | Hybrid Pharma |
Frequently Asked Questions
What is the NDC number assigned to Blt Dmso Gel?
Blt Dmso Gel was assigned by its manufacturer with NDC product code 26436-5382. This product is a drug classified as a human compounded drug. Compounded drugs are medications created by combining or altering existing drugs to meet the specific needs of certain patients. The NDC directory only includes information about compounded drugs from facilities that choose to assign NDC numbers to their products.
Which are the NDC package codes for Blt Dmso Gel?
The NDC package code 26436-5382-1 was assigned to a 30 g in 1 JAR of benzocaine; tetracaine; lidocaine administered topical via gel.
Who manufactures this product?
Blt Dmso Gel is manufactured by an outsourced facility and labeled by Hybrid Pharma. All compounded drugs included in the NDC directory are classified as "Outsourcing Facility Compounded Human Drug Product (Exempt from Approval Requirements)". Outsourcing facilities are a type of drug compounding facility regulated under Section 503B of the FD&C Act could be eligible for exemptions from drug registration if they meet all the conditions specified under Section 503B.
Which are the NDC crossover matchings for this product?
We found 2 matching products that have the same substance, dosage form and administration route. The matching products are manufactured by Hybrid Pharma with NDC product codes 26436-5057-1 and 26436-5433-1.